Pediatric Germ Cell Tumors: A Developmental Perspective

Joshua L. Pierce, A. Lindsay Frazier, James F. Amatruda

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Germ cell tumors (GCTs) arising in infants, children, and adolescents present a set of special challenges. GCTs make up about 3% of malignancies in children aged 0-18 and nearly 15% of cancers in adolescents. Epidemiologic and molecular evidence suggests that GCTs in young children likely represent a distinct biologic group as compared to GCTs of older adolescents and adults. Despite this difference, pediatric GCTs are typically treated with cisplatin-based multiagent regimens similar to those used in adults. There is evidence that children are particularly vulnerable to late effects of conventional therapy, including ototoxicity, pulmonary abnormalities, and secondary malignancies, motivating the search for molecular targets for novel therapies. Evidence is accumulating that the genes and mechanisms controlling normal germ cell development are particularly relevant to the understanding of germ cell tumorigenesis. Perturbations in the epigenetic program of germ cell differentiation, with resulting effects on the regulation of pluripotency, may contribute to the marked histologic variability of GCTs. Perturbations in the KIT receptor signaling pathway have been identified via next-generation sequencing studies and in genome-wide association studies of testicular cancer susceptibility. Here, we review these and other biological insights that may fuel further translational and clinical research in childhood GCTs.

Original languageEnglish (US)
Article number9059382
JournalAdvances in Urology
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Germ Cell and Embryonal Neoplasms
Pediatrics
Germ Cells
Neoplasms
Translational Medical Research
Genome-Wide Association Study
Testicular Neoplasms
Epigenomics
Cisplatin
Cell Differentiation
Carcinogenesis
Lung
Therapeutics
Genes

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Urology

Cite this

Pierce, J. L., Frazier, A. L., & Amatruda, J. F. (2018). Pediatric Germ Cell Tumors: A Developmental Perspective. Advances in Urology, 2018, [9059382]. https://doi.org/10.1155/2018/9059382

Pediatric Germ Cell Tumors : A Developmental Perspective. / Pierce, Joshua L.; Frazier, A. Lindsay; Amatruda, James F.

In: Advances in Urology, Vol. 2018, 9059382, 01.01.2018.

Research output: Contribution to journalReview article

Pierce, Joshua L. ; Frazier, A. Lindsay ; Amatruda, James F. / Pediatric Germ Cell Tumors : A Developmental Perspective. In: Advances in Urology. 2018 ; Vol. 2018.
@article{d87735e5b24c4cee8681f33ba7786cff,
title = "Pediatric Germ Cell Tumors: A Developmental Perspective",
abstract = "Germ cell tumors (GCTs) arising in infants, children, and adolescents present a set of special challenges. GCTs make up about 3{\%} of malignancies in children aged 0-18 and nearly 15{\%} of cancers in adolescents. Epidemiologic and molecular evidence suggests that GCTs in young children likely represent a distinct biologic group as compared to GCTs of older adolescents and adults. Despite this difference, pediatric GCTs are typically treated with cisplatin-based multiagent regimens similar to those used in adults. There is evidence that children are particularly vulnerable to late effects of conventional therapy, including ototoxicity, pulmonary abnormalities, and secondary malignancies, motivating the search for molecular targets for novel therapies. Evidence is accumulating that the genes and mechanisms controlling normal germ cell development are particularly relevant to the understanding of germ cell tumorigenesis. Perturbations in the epigenetic program of germ cell differentiation, with resulting effects on the regulation of pluripotency, may contribute to the marked histologic variability of GCTs. Perturbations in the KIT receptor signaling pathway have been identified via next-generation sequencing studies and in genome-wide association studies of testicular cancer susceptibility. Here, we review these and other biological insights that may fuel further translational and clinical research in childhood GCTs.",
author = "Pierce, {Joshua L.} and Frazier, {A. Lindsay} and Amatruda, {James F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/9059382",
language = "English (US)",
volume = "2018",
journal = "Advances in Urology",
issn = "1687-6369",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Pediatric Germ Cell Tumors

T2 - A Developmental Perspective

AU - Pierce, Joshua L.

AU - Frazier, A. Lindsay

AU - Amatruda, James F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Germ cell tumors (GCTs) arising in infants, children, and adolescents present a set of special challenges. GCTs make up about 3% of malignancies in children aged 0-18 and nearly 15% of cancers in adolescents. Epidemiologic and molecular evidence suggests that GCTs in young children likely represent a distinct biologic group as compared to GCTs of older adolescents and adults. Despite this difference, pediatric GCTs are typically treated with cisplatin-based multiagent regimens similar to those used in adults. There is evidence that children are particularly vulnerable to late effects of conventional therapy, including ototoxicity, pulmonary abnormalities, and secondary malignancies, motivating the search for molecular targets for novel therapies. Evidence is accumulating that the genes and mechanisms controlling normal germ cell development are particularly relevant to the understanding of germ cell tumorigenesis. Perturbations in the epigenetic program of germ cell differentiation, with resulting effects on the regulation of pluripotency, may contribute to the marked histologic variability of GCTs. Perturbations in the KIT receptor signaling pathway have been identified via next-generation sequencing studies and in genome-wide association studies of testicular cancer susceptibility. Here, we review these and other biological insights that may fuel further translational and clinical research in childhood GCTs.

AB - Germ cell tumors (GCTs) arising in infants, children, and adolescents present a set of special challenges. GCTs make up about 3% of malignancies in children aged 0-18 and nearly 15% of cancers in adolescents. Epidemiologic and molecular evidence suggests that GCTs in young children likely represent a distinct biologic group as compared to GCTs of older adolescents and adults. Despite this difference, pediatric GCTs are typically treated with cisplatin-based multiagent regimens similar to those used in adults. There is evidence that children are particularly vulnerable to late effects of conventional therapy, including ototoxicity, pulmonary abnormalities, and secondary malignancies, motivating the search for molecular targets for novel therapies. Evidence is accumulating that the genes and mechanisms controlling normal germ cell development are particularly relevant to the understanding of germ cell tumorigenesis. Perturbations in the epigenetic program of germ cell differentiation, with resulting effects on the regulation of pluripotency, may contribute to the marked histologic variability of GCTs. Perturbations in the KIT receptor signaling pathway have been identified via next-generation sequencing studies and in genome-wide association studies of testicular cancer susceptibility. Here, we review these and other biological insights that may fuel further translational and clinical research in childhood GCTs.

UR - http://www.scopus.com/inward/record.url?scp=85042485394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042485394&partnerID=8YFLogxK

U2 - 10.1155/2018/9059382

DO - 10.1155/2018/9059382

M3 - Review article

C2 - 29515628

AN - SCOPUS:85042485394

VL - 2018

JO - Advances in Urology

JF - Advances in Urology

SN - 1687-6369

M1 - 9059382

ER -